| Nom de l’organisation/du laboratoire/de l’entreprise | ASNR, LRMed ; Fontenay-Aux-Roses |
| Email de contact | fabien.milliat@asnr.fr |
| Qui contacter | FABIEN MILLIAT |
| Intitulé du poste | 18 months Post doctoral position |
| Une offre détaillée : | Background |
| Radiotherapy is used in over 50% of cancer patients during the course of their disease. Radiotherapy induces direct destruction of tumor cells, but also affects the tumor microenvironment, leading to profound changes in the antitumor immune response. Depending on dose, volume and fractionation, radiotherapy can induce immunogenic cell death, as well as activating immunosuppressive signals. With the emergence of immunotherapies, interest in combining radiotherapy and immunomodulators has recently increased, with the use of immune checkpoint inhibitors in particular. |
| Innovative or unconventional radiotherapies that play on irradiation volume or spatial dose fractionation in general are booming, with a strong interest in combining them with immunomodulators. Immune infiltration of tumors is partly controlled by the vascular endothelium. Thus, the relationship between the vascular and immune systems lies at the heart of tumor responses to irradiation, but also potentially to combined therapies. The aim of this postdoctoral project will be to study the relationships between these two compartments using cutting-edge techniques such as scRNAseq and spatial transcriptomics, in order to characterize communication parameters in response to radiotherapy combined or not with immunotherapies. |
| Postdoctoral objective: |
| The aim of the postdoctoral fellow will be to set up in vivo irradiation experiments under innovative radiotherapy conditions at the ASNR (in collaboration with INSERM unit U1030, Dr Michele Mondini, Gustave Roussy) to study vascular and immune tumor responses, using state-of-the-art scRNAseq, flow cytometry and spatial transcriptomics techniques. Tumor models will be performed in immunocompetent mice as xenografts or orthotopic injections. The aim will be to identify mechanistic hypotheses concerning responses, and to identify therapeutic options for optimizing combinations of radiotherapy and immunomodulators. These therapeutic strategies will then be tested and validated in vivo to evaluate their potential efficacy and safety in models of healthy tissue lesions, two parameters essential to their translation to the clinic. |
| The candidate will have doctoral experience in biology in the field of oncology, with experience of immunocompetent mouse models. Expertise in immunology will be appreciated, as well as experience in single cell approaches. Skills required for this position include: Strong skills in biology, oncology, immunology, in vivo approaches, basic coding in R . Excellent communication, didactic and teamwork spirit |
| Type de contrat | Poste à temps plein |
| Type de contrat | Contrat à durée déterminée |
| Poste disponible à partir de | 01-juin-25 |
| Date limite pour postuler | 10-mai-25 |
